Why Change is Needed
If you’ve made a charitable donation to medical research or paid taxes in the last year, your dollars are part of the $40 billion spent annually on medical research at universities worldwide. While your dollars may help to support important basic scientific discoveries in those laboratories, chances are slim to none that those discoveries will ever cross the finish line for patient treatments. The system for funding and conducting medical research and translating that research into patient treatments is broken.
How big is the problem? In the last decade, in spite of a doubling of dollars invested in academic research and commercial research and development, the number of new drugs coming to market has remained flat.
Learn more about the problem:
- Download Where are the cures? (PDF).
- Read a recent Newsweek article that describes the problem (and mentions our solution)
Our Accelerated Research Model
In 2004, Myelin Repair Foundation set out to conduct research in a new, more effective way based on close collaboration between scientists and building relationships with partners in the biotech and pharmaceutical industry.
This new model for research, which we call the Accelerated Research Collaboration Model™ (ARC™), is already succeeding in accelerating discoveries, from 15 years to five years.
Learn more about our model:
Why We’re Different
The Myelin Repair Foundation is the only research organization that addresses every phase in the drug discovery process, from initial research all the way to licensing by commercial drug developers. This is the only way to ensure that promising research results in real patient treatments – in the shortest amount of time. We combine this holistic approach with our renowned scientific team and collaborative research model.
The results are stunning: 19 new potential myelin repair drug targets, 24 new research tools for neurological disease research, 18 patentable inventions, more than 50 articles published in peer-reviewed journals. All in just five years. We’ve also been covered in the major national media and more than 60 different disease research organizations have expressed an interest in our model. We’ve raised $35 million and are on track to raise $100 million more.